GPC Biotech AG Schedules Conference Call For Today, December 20th To Discuss Partnering Agreement With Pharmion Corporation For Satraplatin

MARTINSRIED/MUNICH, Germany, Dec. 20 /PRNewswire-FirstCall/ -- U.S. Research and Development Facilities in Waltham/Boston Mass. and Princeton N.J. -- GPC Biotech AG today announced that it will hold a conference call today, Tuesday, December 20, 2005 to discuss its partnering agreement with Pharmion Corporation. The two companies announced earlier today that they have entered into a co- development and license agreement for satraplatin.

The call will be held today at 15:30 CET/9:30 AM EST. Participants may listen via live webcast, accessible through the GPC Biotech Web site at http://www.gpc-biotech.com, or via telephone. A replay will be available via the Web site following the live event.

The dial-in numbers for the call are as follows: European participants: 0049-(0)69-500-71846 U.S. participants: 1-866-202-1971 (toll-free)

GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. The Company's lead product candidate - satraplatin - has achieved target enrolment in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and GPC Biotech has begun the rolling NDA submission process for this compound. Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc. GPC biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit the Company's Web site at http://www.gpc-biotech.com.

CONTACT: Martin Braendle, Associate Director, Investor Relations &Corporate Communications, +49 (0)89 8565-2693, ir@gpc-biotech.com, orLaurie Doyle, Associate Director, Investor Relations & CorporateCommunications, +1-781-890-9007 ext. 267, usinvestors@gpc-biotech.com, bothof GPC Biotech AG; or In the U.S.: Matt Haines of Euro RSCG Life NRP,+1-212-845-4235, matthew.haines@eurorscg.com; or In Europe: Brian Hudspithof Maitland Noonan Russo, +44 (0)20 7379 5151, bhudspith@maitland.co.uk

Web site: http://www.gpc-biotech.com/